Trevor N Stitt
Regeneron scientist who worked in David Glass and George Yancopoulos's muscle program on the 2001 papers showing that the Akt/mTOR pathway drives muscle growth and protects against muscle wasting
Regeneron Pharmaceuticals, Tarrytown, New York (affiliation on PubMed papers from the early 1990s to 2007)
Trevor Stitt is a co-author of two 2001 Atlas papers from Regeneron that made mTOR central to muscle biology. BOD2001 showed in living mice and rats that switching on Akt makes muscle fibres grow larger, that blocking mTOR with rapamycin stops this growth, and that active Akt can protect muscle from wasting (atrophy). ROM2001 showed in cultured muscle cells (myotubes) that the growth signal IGF-1 enlarges muscle cells through Akt and two branches below it, mTOR and GSK3. Together these papers explain why mTOR is the main switch linking growth signals and exercise to muscle size.
PubMed lists Stitt at Regeneron Pharmaceuticals in Tarrytown, New York, on 23 papers. The earlier ones come from Regeneron's work on growth factors and their receptors in the nervous system. In 1995, as first author in Cell, Stitt reported that the blood-clotting regulator protein S and the related protein Gas6 are the ligands for the Tyro3 and Axl receptor tyrosine kinases. Later papers stay with the muscle program led by David Glass, including a 2004 paper on how IGF-1 and Akt block the switching on of the atrophy enzymes MuRF1 and MAFbx, and a 2007 paper showing that MuRF1 breaks down myosin heavy chain, the main motor protein of muscle.
No official profile was found, so training and current position are not given.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2001 | A | Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo BOD2001 Co-author on the in vivo study showing that Akt/mTOR signalling drives skeletal muscle hypertrophy and can prevent muscle atrophy. |
| 2001 | M | Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways ROM2001 Co-author on the cultured-myotube study showing that IGF-1 grows muscle cells through Akt and both its mTOR and GSK3 branches. |
Co-authors in the Atlas 2
People with a profile here who share at least one study with Trevor N Stitt.
ShowHide
- George D. Yancopoulos 2 shared studies Industry scientist who co-founded Regeneron and led drug discovery there; in this Atlas he is senior author of an early paper showing that Akt/mTOR signalling controls muscle size.
- Sue C. Bodine 2 shared studies Showed that turning on the Akt-mTOR pathway is enough, by itself, to make skeletal muscle grow and to stop it from wasting away
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.